Arch Biopartners Gains U.S. IRB Approval for LSALT Phase II
TORONTO, Canada, August 31, 2026 Arch Biopartners Inc. announced that it has received central Institutional Review Board (IRB) approval...
acute kidney injury
Advertisement
Arch Biopartners Expands LSALT Peptide Phase 2 Kidney Injury Trial to U.S.
TORONTO, Canada, August 11, 2026 Arch Biopartners Inc. announced plans to expand its ongoing Phase 2 clinical trial of...
FarmaMondo Partners with Cordex to Expand Zemcelpro
LUGANO, Switzerland & MONTREAL, Canada, July 16, 2026 FarmaMondo Group has entered an exclusive commercial partnership with Cordex Biologics...
Dimerix Secures Funding to Advance DMX-200 Phase 3 Trial
MELBOURNE, Australia, July 17, 2026 Dimerix Limited has secured an initial AU$10 million non-dilutive loan facility to strengthen its...
Arch Biopartners Accelerates IL-32 Chronic Kidney Disease Drug Program
TORONTO, July 17, 2026 Arch Biopartners Inc. has taken a significant step toward advancing its pre-Investigational New Drug (pre-IND)...
Advertisements
Mission Sells MTX652 to Dimerix in $292M Deal
Cambridge, UK, July 17, 2026 Mission Therapeutics announced the divestment of its Phase 2-ready USP30 inhibitor MTX652 to Dimerix...
SeaStar Promotes Pediatric AKI Awareness
DENVER, July 14, 2026 SeaStar Medical announced its support for multiple educational initiatives aimed at improving the diagnosis and...
CalciMedica Receives FDA Clearance to Continue Auxora KOURAGE Trial
LA JOLLA, Calif., June 24, 2026 CalciMedica, Inc. announced that the U.S. Food and Drug Administration (FDA) has completed...
Edesa Biotech Reports Positive Paridiprubart AKI Data
TORONTO, June 5, 2026 Edesa Biotech, Inc. announced new exploratory analyses demonstrating positive clinical signals for paridiprubart (EB05), its...
Arch Biopartners Advances Phase II AKI Trial
TORONTO, May 22, 2026 Arch Biopartners announced that Royal Columbian Hospital (RCH) in British Columbia has dosed its first...
Advertisement
